Trials / Completed
CompletedNCT02351739
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK Study)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- Acerta Pharma BV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Metastatic Urothelial Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pembrolizumab | |
| DRUG | ACP-196 in combination with pembrolizumab |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2018-02-01
- Completion
- 2018-04-01
- First posted
- 2015-01-30
- Last updated
- 2019-09-10
- Results posted
- 2019-09-10
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02351739. Inclusion in this directory is not an endorsement.